THE RECOVERY KERNEL

□□□ □□□ □□□□□ □□□□□□

□□□□ □□□□□□□□□□□□ (DXM) □□□ □□□□ □□□□?

* □□□□□□□□□□□□ (DXM) □□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□
* □□□□ □□□□□ □□□□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□
* □□□□□□ □□□□ □□□□ (Recovery Kernel) □□ □□□□□□
* □□□□□ (Naloxone) □□□□□
* COMT □□ DRD2 □□□□□□ □□□□□□□□ □□□□□
* MTHFR □□□□ □□□□□
* □□□□□ □□□□ (Blueprint) □□□□□
* findahelpline.com □□ □□□□ □□□ □□□□□

□□□□□ □□□□ □□□□□ □□□□□

DXM · □□□□□□□□□□□□ · □□ · □□□□□□□□ · □□□□ □ · □□□□□ · DM · □□ □□□ · □□□□

⚠ □□□□ □□□□□ □□□ - □□ □□□□□ □□□□ □□□□□ | □□□ □□□□ 907 □ □□□□ □□□ findahelpline.com □□□ texting □□□□□

DXM □SSRI □□□ MAOI □□ □□□□□ □□□□ □□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□

□□□ □□□□□□ **(**□□□□□□ □□□□□□ □□□□ □**)** □□□□ □□□□ □□□ □□□ □□□□□□ □□□□□□□ □□□□□ □□□ □□□□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□□□ □□□ □□□ □□□□□ □□□□□□□□ □□□□□ □□□ □□□

CYP2D6 □□□□ □□□□□□ □□□□ □□□□ □□□□□□ (DXM) □ □□□□□ □□□□ □□□□□□□□□□ □□□□□ □□□□ □□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□ □□ □□ □□□

□□ □□□ □□□□□ □□□ □□□□ □□□□□ □□□□ □□□□□ □□□

□□□□□ □□□□□ □□□ □□□□□ □□□□□□ (DXM)□ □□□□□□ □□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□ □□ □□□□ □□ □□□ □□□ □□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□ systematic □□□□□□ □□□□ □□□ □□□□□ □□□□□□□ □□□□ □□□□□.

□□□□ □□□□□□□ □□□□ □□□□□ □□□□ "□□□□□□□ □□□□ □□□□ □□□ □□□□ □□ □□□ □□□□ □□□□□□" □□ □□□ □CYP2D6 □□□□□□□□□ □□□ □ documented □□□□□□ □□□ □□□□□ □□□□□ □□□□□ ضعيف□ □□□□□ □□ □□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□□ □□□□□ DXM □□□ □□□□□□ □□□ □□□ □□□□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□□ CYP2D6 □□□ □□□□ □□□□□□□ □□□□ □□□ □□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□ □□□ abusive □□□□□ □□□-□□□□□ □□□ □□□□□ □□□□□ □□□ □□□ □□□□□□ □□□ □□□ □□□□□□

□□□□□ □□□□□□-□□ □□□□ □□□ □□□□□□□□ □□□□ □□□□□□□ □□□□ □□ □□□□ □□□□□□ □□□ □□□□ □□□ □□□□□ □□□□ □□□□□□ □□ □□□□□□ (DXM) □□□□ □□□□ □□□□□□ □□□□□ □□□□ □□□ □□□□□ □□□□□□ □□□□ □□□ □□ □□□ □□□□□ □□□□ (NyQuil) □□□ □□□□□ (DayQuil) □□□□ □□□□□□ (DXM) □□ □□□□□□□ □□□□□ □□□ □□□□ □□ □□□□ □□□ □□□ □□□ □□□ □□□□ □□□ □□□□□ □□□

□□□□□ □□ □□□□□□ □□□□ □□ NMDA □□□□□□- DXM □□□□□ □□□□□□□□ □□□□□□ □□□□ (NMDA) □□□□ □□□ □□ □□□□ □□□ □□□□ □□□□□ □□□ □□□ □□ □□□□□□ appealing □□□□ □□□ □□□ □□□□□□□ □□□□ □□□□□□ □□□ □□□ □□□□□□ □□□□□□ "□□" □□□□□ □□ □□□□ □□□□ □□ □□□ □□□□ □□□□□ □□□□ - □□□ □□ □□ □□□□ □□□ □□□□ □□□ □□□□□ □□□□□ □□ □□□ □□□□ □□□□□ □□ 8 □□ □□ □□□□ □□□ □□□□ □□□□□ □□□ □□□□□□□□ □□ □□□□□ □□□ □□□□□□ □□□ □□□□ □□□ □□□□□ □□□□□ □□□ □□□□□□

DXM □□□□□ □□□□□□□□ □□□ □□□□□ □□□□ □□□ □□□ □□□□ □□□ □□□□ □□□□ □□□ □□□ □□ □□□ □□□ □□□□□ □□□ □□□□ □□□□□□ □□□ □□□□ □□ □□□□ □□ □□□□ □□□□ □□□□ □□ □□□□ □□□ (□□□□□ □□□ 2:00) □□□□ □□□□□□ □□□□□ □□□□□□ □□ □□□ □□□ □□□ □□□□□ □□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□ □□□□ □□□□□□ □□□ □□□□ □□ □□□ □□□□□□ □□□ □□□□□□□ □□ □□□□□□ □□□□ □□□ □□□□ □□ □□□□□□ □□□□ □□ □□□□ □□□□□ □□□ □□□□ □□□□□□

□□□ 0□ □□□□ □□□ □□□□□□ □□□ □□□□ □□ □□□□□□□□□□□□ (DXM) □□□□ □□□□ □□ □□□ □□□□□□ □□□□□ □□□ □□□□ □□□□

□□□ 0 - □□□ □□□□□□ □□□□ □□□□□□

⚠ □□□□□□□□ **(DXM)** □□□□ □□□ □□□□ □□□□ □□□ □□□□ □□□ □□□ □□□

0.1 — □□□ □□□ □□□□□□ □□□□□ □□□□□□: □□□□□ □□□ □□ □□□□□□

□□□□ - □□□□□□□□ □□□□ □□□□ **(OTC)** □□□ □□□□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□□□□□ - "□□□□□□□" □□□□□ □□□ □□□□□□□.

DXM □□□□□□ □□ □□□□□ □□□ □□□ □□ □□□□□ □□ □□□□□ □□□□ □□□ □□□ DXM□ □-DXM □ □□□□□□□□ □□□□□□ □□□□□ □□□□ □□ □□ □□□□ □□□ □□□ □□□□ □□ □□□□□ □□□□□□ □□□□□ □□□ □□□□ □□□ □□□ □□□□□ □□□□□ □□□□□□ □□□ □□□□ - □□□ □□□ □□ □□□□□□ □□□ □□□ □□□□□ □-DXM □□□□ □danger □□ □□□ □□□ □□□ □□□□ □danger □□□

□□□□□□	□□□□□□	□□□□□ □□ □□□ □□□ □□□ □□□ □□□□□□	□□□□ □□ □□□ □□□□□ □□□□ * □□□ □□□ □□□□□ □□□□ □□□ □□□□□ * □□□□□□□ □□□□□ □□□ □□□ □□□□ * □ **breathing** □□□□□ * □□□□□ □□ □□□□□□ □□□□ □□□□ * □□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□ * □□ □□□□ * □□□□ **blurred** □□□□ * □□□□ □□□ □□□□□ * □□□□□ □□□□ □□□□□□- □□□□□ □□□□□ □□□ □□□ □□□□□ □□ □□□□ □□□□ □□□□□ □□□
□□□□□□□ (□□□□ / □□□□)	NyQuil□ DayQuil □□ □□□ □□□ □□□□□□□	□□□□□□□ (□□□□□□□□ □□□) □□□□ 4 □□□ □□□ □□□□ □□□ □□Adults □□□ □□□□□□□□ □□□□ □□□□□□□ □□□ □□□□□ □□□□ □□□□□□ □□□ □□□□ □□□□□ - □□□□□ □□□□□ □□□ 24-72 □□□□ □□□ □□□□□	□□□□ □□□□□□ □□□ □□□□□□ □□□□□ 600□□□ □□□ □□□□□□ (NAC) □□□□□ □□□ □□□ □□ □□ □□□□ □□□□□□ □□□ □□□□□□ □□□ □□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□□□ □□□□□ □□□ □□□□ □□□□□□ □□□□ □□□ □□□□□□ □□□
□□□□□□□□ (□□-□□□□ □□□□□)	Coricidin Cough & Cold (Triple C) - □□□ □□□□ □□□□ DXM □□□□	□□-□□□□□□ □□□□ □□□□ □□□□□ □□ □□□□ □□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□ □□ □□□□ □□□□ □□□□□□ □□□ □□	□□□□□□□□ □□□□ □□□ □□□□ □□□□□□□ □□□□ 907 □ □□ □□□□□ □□□□□□□□□ □□□□□ □□□□□ □□□ □□ □□□□□ □□□ □□□ □□□□□ □□□

		[illegible] (Triple C) [illegible]	[illegible]
Gu[illegible] ([illegible])	[illegible]	[illegible] DXM [illegible] uncomfortable [illegible]	[illegible]
[illegible] ([illegible])	Sudafed PE DM[illegible]	[illegible] (DXM) [illegible]	[illegible]-[illegible] 907 [illegible]
DXM [illegible] - [illegible]	Delsym ([illegible] полісти[illegible]), [illegible] Robitussin 12-[illegible]	[illegible] (DXM) [illegible] (SSRIs) [illegible]), [illegible]	[illegible] (DXM) [illegible]тному [illegible]

⚠ CORICIDIN COUGH & COLD (TRIPLE C) [illegible]fog[illegible] (DXM) [illegible] TRIPLE C [illegible]

0.2 - [illegible]

⚠ [illegible] **(DXM)** [illegible]

DXM [illegible] SERT [illegible]

- SSRIs (Prozac/fluoxetine, Zoloft/sertraline, Lexapro/escitalopram, Celexa/citalopram, Paxil/paroxetine): [illegible] SERT [illegible] - [illegible] DXM [illegible] CYP2D6 [illegible] DXM [illegible] DXM [illegible]
- SNRIs ([illegible]/[illegible] [illegible]/[illegible]): [illegible] νo[illegible] - [illegible] DXM [illegible]
- MAOIs ([illegible] [illegible]/[illegible]): [illegible] - [illegible] DXM [illegible]
- [illegible] (DXM) [illegible]
- [illegible] ([illegible]-[illegible]): [illegible]

[illegible]: [illegible] muscle[illegible] ([illegible])، [illegible] 907 [illegible]

CYP2D6 [illegible] CYP2D6 [illegible] DXM [illegible] DXM [illegible] accumulate [illegible] SERT-inhibiting [illegible] CYP2D6 [illegible] DXM [illegible]

0.3 - [illegible]

[illegible]	[illegible]	Response
[illegible]/[illegible] [illegible]	[illegible]	[illegible] 907 [illegible] danger [illegible] ([illegible]) [illegible]

	[illegible]	[illegible] 'DXM - [illegible] - [illegible]'
[illegible] ([illegible] [illegible]).	[illegible] [illegible] [illegible]

□□□ 1 - □□□□□□□□ (DXM) □□□□ □□ □□□□□□ □□□□

□ □□□□□□□ - □□□□ □□□□□□□ □□□□□□ □□ □□□□□□ □□□□□□□ □□□□□□ □□□ □□□ □□□□□□□ □**igma** □□□□□ □□ □□□□ □□□□□□ □□□□□□

DXM □□□□□□□□□ □□□□ □□□□□□□ □□□□ □□□□□ □□□□□□ □□□□□ □□□□□□ □□ □□□□ □□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□ □□ □□□□□□ □□□□ □□ - □□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□□ - □□□□□□ CYP2D6 □□□□□□ □□ □□□□□ □□□□ □□□□□ □□-□□□□□ □□ horrifying □□□□□□□ DXM □□□□□ □□□□□□ □□ □□□□□□□□ □□□□□□□ □□□□□ □□ □□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□□ □□ □□□□□ □□□□□□□ □□□□□□□

1.1 - □□□□ □□□□□□□ □□□□□□□

□□□□□□ □□□□□□	**DXM** □□□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□□ * □□-□□□□□ **(antidepressant)** * □□-□□□□□□ **(antiemetic)** * □□-□□□□□ **(antitussive)**	□□□□□ □□□□□□□□□
NMDA □□ □□□□ □□□□□□ (□□□□ - □□□□□□□□□ □□□□).	DXM □ CYP2D6 □□□□□□ □□□□□□□□□ □□□□□□ □□□□ □ DXM □□□□□ □□□□□ NMDA □□□□□□□□ □□□□□ □□□□ □□□□□□□□□ □ NMDA □□□□□ □□□□□□ □□ □□□□□□ □□□□□□ pharmacological □□□□□□ □□□□□ □□□□ dissociative □□□□□ DMN □□□□ □□□□ □□ □□□□□ □□ □□□□□ □□□□ □□ "ego dissolution" □□□□□□□□	NMDA □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□ □□ □□□□□□ □□ □□□□ □□□□□□□□□ □□□□□□□ □□□□ □□□□ □□ □□□□□ □□ □□□□ □□□□ NAC □□ □□□□□□□ □□□□□ □□□□□□ □□□□□□□□□ □□ □□□□□□□ □□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□ □□ □□ □□ □□□□□□ DXM □□□□□□ □□□□ □□ □□□□□□ □□□□□□□□ □□□□
□□□-1 □□□□□□□	DXM □□□□ (□□□□□□□□□ □□□□□) □□□□-1 □□□□□□ □□□□□□□□ □□□□ □□□□ □□□□ □□□□-1 □□□□□□ □□□□□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□-1 □□□□ □□□□□□□ DXM □□ □□□□ □□□□□ □□□□ □□□□ □□ □□□□ □□□□□□ □□□□ □□ □□□□ □□□□-□□□□ □□□□ □□□□ □□□□□□□	□igma-1 □□□□□□ □□□□□ DXM□ □□□□□□ □□□□□ □□□□ □□□□ □□ □□□□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□ □DXM □□□□□□□ □□□□□□□ □□□□□ □□□□□□ □DXM □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□ □igma-1 □ □□□□□□ □□□□□□ □□□□ □□□□□□ CYP2D6 □□□□□□□□ □□□□ (□□□□□□□□□ □□□□□□)□ □□□□□ DXM □□□□□ □□ □□□□□□□□□□□ □□□□□ □igma-1 □□□□□□ □□□□□ □□□□□□
□□□□□□ □□□□□□□□□ (SERT) □□□□□□□	DXM □□ dextrorphan □□□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□ □□□□□□ □□□□□□	□□□□□□ □□□□□ □□□□□□ MDMA □□□□□□□□ □□□□□□ □□□□ □□ □□□□ □□□□ □□□□□□□□ 5-HTP □□□□□□□ □□□□□□□ □□□□□□ □□□□ □□□□ SERT □□□□□□ □□□□□□

	[illegible] SSRIs [illegible] SERT [illegible] DXM [illegible] DXM [illegible]	[illegible] 5-HTP [illegible] (SERT [illegible]) [illegible] DXM [illegible] 3–5 [illegible] 5-HTP [illegible]
[illegible]-[illegible] ([illegible])	DXM [illegible]-[illegible] [illegible]ç[illegible] ([illegible]) [illegible]	[illegible] (1000mg+), [illegible]فس [illegible] DLPA ([illegible]) [illegible] DXM [illegible]

1.2 - CYP2D6 [illegible]

[illegible] - [illegible]

[illegible]: "CYP2C9" [illegible] '[illegible] CYP2D6 [illegible]' [illegible]-DXM[illegible] CYP2D6 [illegible]-DXM [illegible]

CYP2D6 [illegible]	[illegible]DXM [illegible]	[illegible]
[illegible] ([illegible])	DXM [illegible] ([illegible] NMDA [illegible]) [illegible] -[illegible] NMDA[illegible] DMN[illegible] "[illegible]" [illegible] Sigma-1 [illegible] SERT [illegible] NMDA [illegible]	[illegible] (NMDA) [illegible] ([illegible]-[illegible])[illegible]
CYP2D6 [illegible] ([illegible] 7-10%; [illegible] 1-2%).	DXM [illegible] DXM [illegible] DXM [illegible] NMDA[illegible] SERT[illegible] [illegible]igma-1[illegible]	[illegible] (DXM) [illegible] (SSRI) [illegible] [illegible]SER[illegible] [illegible]

	[illegible] igma-1 [illegible] DXM [illegible]	[illegible]
CYP2D6 [illegible] (~1% [illegible] 2%).	DXM [illegible]	DXM [illegible] documented [illegible] (NMDA) [illegible] CYP2D6 [illegible]، [illegible]
CYP2D6 [illegible]	[illegible] (SSRI) [illegible] 2 6 [illegible] (DXM) [illegible] (SSRI) [illegible] قت [illegible]	DXM [illegible] Prozac [illegible] DXM [illegible] Paxil [illegible]

1.3 - [illegible]

[illegible] - [illegible]

[illegible] (DXM) [illegible] "[illegible]" [illegible] "DXM FAQ" [illegible] "[illegible]" [illegible]

[illegible] ط [illegible]	approximated [illegible]	[illegible]	[illegible]
[illegible]	100-200 [illegible]	[illegible] perceived [illegible]	[illegible] igma-1 [illegible] SERT [illegible] NMDA [illegible]

			[illegible]
[illegible]	200-400 [illegible]	[illegible]	[illegible] ([illegible] CYP2D6 [illegible])[illegible] NMDA[illegible] [illegible]
[illegible]	400-700 [illegible]	[illegible] "M-[illegible]" [illegible] "K-[illegible]" [illegible]	[illegible] NMDA [illegible] (DMN) [illegible] Σ1 [illegible] - [illegible] DXM-[illegible]
[illegible]	700–1500mg+	[illegible]قطع [illegible]	[illegible] NMDA [illegible]

1.4 - [illegible] (DXM) [illegible]? "[illegible]" [illegible] diagnostic [illegible]

[illegible] - [illegible]

[illegible] (DXM) [illegible]

DXM [illegible]- * [illegible] * [illegible] * [illegible]	[illegible]	[illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible] * [illegible]
[illegible] - [illegible]	[illegible] depress[illegible] ADHD— [illegible] DXM [illegible] (DMN suppression) [illegible]	[illegible] ([illegible]) [illegible]/[illegible]/[illegible]

	[illegible]	
[illegible] - [illegible]	[illegible] (DXM) [illegible]-1 [illegible]	[illegible] (5-HTP[illegible]). [illegible]
[illegible] - [illegible]	[illegible] (ADHD) [illegible] (DXM) [illegible] NMDA [illegible]-1 [illegible] ([illegible]) [illegible] (prefrontal cortex) [illegible]-[illegible]	[illegible] (ADHD) [illegible]-стимулятор [illegible] ([illegible]) [illegible] стимулятор [illegible] (DXM) [illegible].
[illegible]	[illegible] (DXM) [illegible] pharmacological [illegible]	[illegible] - [illegible] NSDR ([illegible] Від[illegible]), [illegible] - [illegible] LSD [illegible] DMN ([illegible]) [illegible]
[illegible]	DXM [illegible] ([illegible]) [illegible]	[illegible]

1.5 - [illegible]

[illegible] - [illegible]

DXM □ □□□ □□□□□ □□□□ □□□ □□□□ □□□□ □□□ □□□□□ □□□□ □□□□ □□ □□□□□□ □□□□□ □□□□□□ □□□□ "□□□□□ □□ □□□□□ DXM □□□□□ □□□□" (1990□□ □□□□ □□ □□□□ □□□ □□□□□ □□□ □□□□□ □□)□ □□□□□ "Erowid-þ DXM □□□□□□" □□ Reddit □□ □□□□ DXM □□□□□□ □□□□□ □□□□□ □□□□ □□□□□□□ □□ □□□□□□ "□□□□□ □□□□" □□□□□□ □□□ □□□□□□□ □□□ □□□□ □□□ □□□□□ □□□□□□ □□□ □□□□□ □□□ □□□□□documented □□□□□ □□□□□ □□□□ □□□ □□ □□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□ □□ □□□□ □□□□□ □□□□□□ □□□ □□□ "DXM □□□□ □□□ □□□□ □□ □□□□□ □□□ □□□" □□□□□□ □□□□□□ □□ □□ □□□□□□□

□□ □□□□ □□□ □□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□□□ □□ □□□□□□□ "□□□□ □□□□□" □□□□ □□□□□□ □□□□□ □□□□□ □□□□□□ CYP2D6□ □□ □□□□ □□□□□□□ □□□ □□□□ □□□ □□□□ □□□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□ □□ □□□□□□□□ DXM □□□□□□□ □□□□□ □□□□ □□□□ □□□□□□□ □□ DXM □□□□□□ □□□□□□ □□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□ (□□□ □□ □□□□□□ □□□□ □□ □□□□□□□).

□□□ 2 - □□□□□□□ □□□□□ □□□□

DXM □□□ □□□□ □□ □□□ □□□□□□ □□□□□ □□□ □□□ □□□□ □□□ □□□□ □□□ □□□□□ □□□ □□□ □□□□□□ CYP2D6 □□□□ □□□ □□□ □□□ □□□□□□ □□ □□□ □□□□□□ □□□□ □□ □□□□ □□□□□ □□□□□ (receptor systems) □□ □□□□□□□ □□□ □□□□□□ □□□□□ □□□□ □□ □□□ □□□□ □□□□ (phenotype) □□□□□ □□□□ □□ □□□□□□ □□□

□-DXM □□□□ □□□ □□□□□□□ □□ □□ □ □□□□ □□□□

□□	□□□□□□□□	□□ □□□□□	□□□□□□□□□□□ (DXM) □□□□ □□□□□□□□
CYP2D6	□□□ □□□□□□ □□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□□ □□□□□□ (□□□ □□□□ □□□□□□ □□□□ □□□ □□□ □□□ □□□)	*4/*4 □□□□ □□□□□□ □□□ (7–10% □□□□□□); *1/*1 □□□□; □□□ □□□ □□□□□.	DXM-□ □□□□□□ □□ □□ □□□ □□□ □□□□ □□□□ □□□ □□ □□□ □□□ □□□□ □□□□□□ □□□□□□ CYP2D6 □OTC □□□□□□ □□□□□ □□ □□□□ □□ □□□□□□□ □DXM: □□□□ □□□□□□□□ DXM (sigma-1 □□ SERT □□) □□□ □□□ □□□ □□□□□ □□□□□□□□ NMDA □□□□□ □□□□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□□ □□□ □□□ □□□□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□ □□□ □□□□ □□□ CYP2D6 □□□□□□ □□□□□□ (□□□□□□□ □□□□□□□□ □□□□□□)□ □□□□□□□□ □□ □□□□ □□□□□□□□ □□□□□□ □□□□□ CYP2D6-□□□□□ □□□□□ □□□□□□ □□□ □□□□ □□□□ □□□□□ □□□
SLC6A4 / 5-HTTLPR	□□□□□ □□□□□□□□ □□□□ □□ □□□□□□□	□□□/□□□ □□□ (SER □□□□□□□□ □□□ □□□□).	SLC6A4 □□□ □□□□ "short/short" □□□ □□□□ □□□□ SERT □□□□□□ □□□□ □□□□ □□□ □□□□□□□ DXM □SERT □□ □□□□□□ □□□□□ □□ □□□□ □□□ □□□□ □□□□□ □□□□□ □□□ □□ □□□□ (□□□□ □□□□□□□ □□□) □□ □□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□ □□□□□□ "Short/short" □□□ □□□□ □□ CYP2D6 □□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□ DXM □□□□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□ □□□ □□□□□ □□□□□ □□ □□□□
HTR2A	5-HT2A □□□□□ □□□□ - □□□□□□ (DXM) □ □□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□ □□□□	□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□.	DXM-□ □□□□□□ σ1-□□□□ □□□ □□ □□□□ □□□ □□□ NMDA □□□□□□ Ψ□□□□□□ □□□□□ □□□□□□ □□□□□ 5-HT2A □□□□□ □□□□□ DMN (Default Mode Network) □□□□□ □□□□□ □□□□□ HTR2A □□□□ □□□ □□□ □□□□ □□□□ DXM □□□□□□□ "□□□□" □□□□ Ψ□□□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□□□□ HPPD (Hallucinogen Persisting Perception Disorder) □□□ □□ □□□□□ - □□□□ □□□ □□□ DXM □□□□ □□□ □□ □□□□□ □ perce□□□□ □□□□□ LSD-□ □□□□□□ HPPD □□ □□□□□ □□□□□

			□□□□□□□
COMT	□□□□□ □□ □□□□□ □□□□□□ □□□□□ □□□□□□□	Val158Met (rs4680)	COMT Met/Met (□□□□□ delayed □□□□□□ □□□□) □□□□□□ □□□□□ □□□□□□ □□□□□□□□ (DXM) □□ □□□□□□□ "Sage" □□□□ □□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□□□□□ (DXM) □□□□□□□ σ-1 □□ NMDA □□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ "Sage" COMT □□ □□□□ □□□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□ NMDA □ormalization □□□□□ □□□□□□□□
MTHFR	□□□□□□□ - □□□□ □□□□□□ □□ □□□□ □□□□□□□□□□□□ □□□□□	C677T (rs1801133), A1298C (rs1801131)	MTHFR □□□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□ □□□□□□□ □□□□ □□□□□ □□ □□□□□□□ □□□□□□□ □□□□□□ □□□□ □□□□□□□□ (DXM) □□□□□□□ □□□□□□□ □□□□□□ 5-MTHF □□□□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□□□□□ (DXM) □□□□□□□□□ □□□□ □□□□ □□□□□□ □□□□
DRD4 / DAT1 (□ ADHD □□□□□□□ □□□□)	□□□□□ □□□□□ - □□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□□□□	DRD4 7-□□ repetitive (rs1800955); DAT1 10-□□ repetitive (rs28363170)	□□□□□□□ (ADHD) □□ □□□□□□□ DRD4 7-□□□□□ □□ DAT1 10-□□□□□ □□□□□ □□□□□□□□□□□□□ (DXM) □□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□γν□□ □□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□ □□□□□□□□□ □□□□□ □□□□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□□□□ □□□□ □□□□

□□□□□□ □□□□□ □□ □□□□□

- DXM □□□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□□? □□□□□□ CYP2D6 □□□□□ □□□□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□□ DXM □□ □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□□ Ή: SSRI □□ □□□□□□□ CYP2D6 □ □□□□□□□ □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□□□□ □□□□□□ □□□□□□
- □□□□□□□□□□□□□ (DXM) □□□□□□□ □□□□□ □□□□ □□ □□ □□□□ □□□□□ □□□□□□□□ □□□□□□□ □□□□□□□ □□□□□ □□ □□□□-1 □□ □□□□□□ □□□□□□□ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□ NMDA □□□□□ □□ □□□□ □□□□□ □□□□ □□□□ CYP2D6 □□□□□ □□□□□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□ (DXM □□□□ □□□□□□□□□□□□ □□□□□ □□□□□ □□□□□□)□
- □□□□□□□□□□□□□ (DXM) □□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□

    * CYP2D6 □□□□□ □□□□□□□ □□□□ □□ □□□□□
    * SLC6A4 □□ "□□□□/□□□□" (short/short) □□□□ □□□□□ □□□□□ □□□□□
    * □□□□□ □□ □□□□□□□ □□□□□□ □□ □□□□□□ □□□□□□

- DXM [illegible] [illegible] ([illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] ADHD-esque [illegible] [illegible] [illegible] [illegible]? → DRD4 7-repeat + DAT1 10-repeat ADHD [illegible] ADHD [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] (DXM) [illegible] [illegible] [illegible] persistent [illegible] [illegible] [illegible] [illegible] HPPD-esque [illegible] [illegible] [illegible]? → HTR2A [illegible] [illegible] [illegible] [illegible] [illegible] 4.4 [illegible] [illegible] DXM [illegible] [illegible] [illegible] HPPD[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□ □ - □□□□□ □□□□□ (DXM) □□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□ □□ □□□□□□□□

□ □□□□□□ - □□□□□□□□ □□□□□ □□ □ - □□ □□□□ □□□□□□ □□□ □□□□□□ □□□ □□□□□ □□□

DXM □□□□ □□ □□□□□□□□□ □□□ □□□□□□ □□□□□□ □□□□□ □□□ □□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□ □□□□□□□ □□□□□□ □□□□□ □□ □□□□□ □□ □□□□□ □□□ □□□ □□□□ □□□□□ NMDA □□□ □□□□□ □□□□□ □□□□ □□□□□□ HPPD (□□□□□□□ distorted □□□□) □□□□ □□□□ □□□□ □□□□□□ □□□□□ □□□ □□□ □□ □□□□ □□□ □□□□□ □□zust□□ □□□□□ □□□□□ □□□ □□□

□□□□□□□□□□□□ (DXM) □□□□ □□□□□□□ □□ □□□□ □□ □□□□□□ □□□□ □□□ □□□□ □□ □□□□□□ □□□ □□ □□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□□□ □□□□□ (OTC), □□□ □□□ □□□ □□□ □□ □□□□□□□ □□□□ □□□□□ □□ □□□ □□□ □□□□□ □□□□□□□ □□□□□□ □□□□□□ □□ □□□ □□□□□ □□□□□□ □□□□□ - □□□□ □□□ □□□ □□□□□□ □□ □□□□□ - □□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□ □□ □□□ □□□□□ □□□□□□ □□□□□ □□□ □□□□□ □□□ □□□ □□□ □□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□□□ □□□□□ □□ □□ □□□□□□

3.1 - □□□□□□ □□□□ □□□□ □□ □□□□ □□?

□□□□□□□	□□□ □□□□□□□□□□□□ (DXM) □□ □□ □□□ □□?	□□□□ □□□□
OTC □□□□□□□	□□□□□ □□□□□ □10 □□□□□ □□□□□ □□□□□ □□□□ □□□□□□ □□□ □□□□ □□□ □□□ □□□□ □□□□ □□□ 8 □□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□ □□□ □□□ □□□ - □□□□□ □□□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□□□ □□ □□□□ □□□ □□□□□□□ □□□□□□□ □□ □□□□ □□□ □□□□ □□□ □□□□□□ □□□□ □□□□□ □□ □□□ □□□□□□□□ □□ □□□ □□□□□□	□□□□ □□□□□□□ □□□□ □□□ □□□ □□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□□ □□□ □□□□□ □□□□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□ □□□□ - □□ □□□□□□ □□□□□ □□□□□□ □□ □□□□□
□□□□□ □□□□□□□	DXM □□□ □□□□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□□□ □□□ □□□ □□□□□ □□□□□□□ □□ □□□ □□□□□ □□□□ □□□□ □□ □□□□□□ □□□ □□□□ DXM □□□□□□ □□□□□□ □□□ □□□ □□ DXM □□□□ □□□□ □□□□ □□□□□ □□□ □□□□ □□□ "□ coughing □□□□ □□ □□" □□□□□ □□□ □□□□ □□□□□ □□□ □□□□□□ □□ □□□□□ □□□□□ □□□□□ □□□ □□□□□□ □□□ □□□□□□	□□□□□ 13 (□□□ □□□□□ □□□□)□ DXM□ □□□□□□ □□ □□□□□ □□□□□□ '□□□□□□□□□□□ □□□□ □□□ □□□□□□ □□□ □□□□□□ □□□□□□ □□□□□ □□□□ NMDA □□□□□ □□□□□□ □□□□□ □□□□ □□□□□ □□ □ persistent perceivable disturbing □□□□ □□□□□□ □□□' □□ □□□□ □□□□ □□□□ □□□ □□□□□ □□□□ □□□ □□□□□ □□□□□
□ adolescent context.	DXM □□□□□ □ adolescent□□ □□ □□□□ □□□ □□□□ □□□ □□ □□□□ □□□ □□□ □□□ □□□ □□ □□□ □□□□ □□□□ □□□□□ □□□□□□ □□□□□□ □□ □□□□□ □□□□□ □□□□□	□□□□□ □□ □□□□□ □□□□□ □□□□□ □□□ □□□□□ □□□ □□□□□ □□□ □□ □□□□□□ (DXM) □□□□ □□□□ □□□□□ □□□ □□□ □□□□ θεραπευτής □□□□□□□ □□ Adolescent □□□□

	□□□□□ □□□□ □□□□ □□ □□□□ □□ adults □□□□□ □□□□□ □□□□□ □□ □□□□□□□□ □□□ □□ □□ □□□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□ □□□ □□□□ □□□ □□□□□ □□□□ □□□□□	□□□□ (□□□ □□□□ □ формування□ □□□□□ □□□□□□□ □□□□□□ □□□□□) □□□□ □□□□ □□□□ □□ □□□ □□□□□□ □□□□
□□□□ □□□□ □□□□□	□□□ □□□□□ (DXM) □□□□□ □□□ □□□□ □□□□□□ □□□ □□□□□ □□□□□ □□□□□ □□ □□□□□ (NyQuil) □□□□ □□ □□□ □□□□ □ (Triple C) □□□□□ □□ □□□□ □□□□ □□□ □□□□ □□□□□	□□□□□ □□□□□ □□□ □□□□ □□ □□□ □□□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□ □□□ □□□ □□ □□□ □□□□□ □□□ □□□ (AST, ALT) □□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□ □□□□□ □□□ □□□ □□ □□□ □□□ □□□□ □□□□ □□□□□

3.2 - □□□ □□□□ □□ □□□ □□□□ □□□□ □□□□ □□□□□□

□□ □□Jerry□	□□□□□□□.	□□□□□	□□□□ □□□□ □□□ □□□□□?
□□□□ □□□□ □□□ □□□ □□ □□□ □□□□□ (□□□□□).	NMDA □□□□□□ □□□□ □□□ □□ □□□ (□□□□□□□ □□□□□); □□□□ □ □□□□; □□□□□ □□□□ □SERT □□□□□ □□□□ □□□□□; □□□□□□ σ1 □□□□ □□□□□ □□□ □□□ □□□□□	□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□ □□□ □□□□ □□□□□ (HPPD-esque)، □□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□□ □□□□□ disturbed.	NAC □□ □□□□□□ □□□□□ - □□□□ □ □□□□□ □□ NMDA □□□ □□□□ □□□ □□□□ stimulating □□□□ □□□□□□ □□□□ □□□□ □□□□□ □□ □□□□ 4-7-8 □□□□□□ □□□
□□□ 1-7	NMDA □□□□ □□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□ □□□-1 □□□□ □□□ □□□□□□□ □□□□ □□□□ □□□□ □□□□□□	□□□ depress□ (□□ □□ □□□□ □□□)— □□□□□□□□□□□ (DXM) □□□□□□ □□□ □□□□□ □□□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□□□ □cloud□□□ □□□ □□□□ □□□ □□□□ □□□□□□ □□□□□ □□□□□ □□□□	□□□ □□□ □□□□□ (□□ECTION 4). 5-HTP □□□□ □□□ □□□□ □□□ □□□ □□ □□□□ □□□□ (□□□□□ □□□ □□□□□ - SERT □□□ □□□□□□ □□□□□□ □□□ □□□□□ □□□ □□□ □□□□ □□□□□□) □□□□ □□□ □□□□□□ □□□□□□ □□□ □□ □□□□ □□□□□ □□□ □□□ □□□□□□□ □□□□ □□□□□ □□□ □□□□□
□□□□ 2-8□	□□□ □□□□□ □□ □□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□ ент□□□□□ (HPPD) □□□ □□□□□ □□□□□ □□□ □□□□ □□□ □□□□□□□ □□□□□□□□□□□ (DXM) □□□□□ □□□□□□ □□□□□ □□ □□□ (ADHD, □□□□□ □□□) □□ □□□□ □□□□□ □□□□□ □□□□□□ □□□	□□□□تق□□ □□□□□ □بعض □□□ □□□□ □□ □□□□□ □□□ □□□□ □□□□□ □□□□ □□□ □□□□□ □□□ □□□ □□□ □□□□□ HPPD □□□□□ □□□□ □□□ □□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□ □□□□□ □□□□ □□□□□	□□□□□□ □□□□□□□ □□□□ □□□□□ (ADHD□ □□□ depressed□□□ □□□□) □□□□ HPPD □□□□ □□□□ □□□□ □□□□□□ □□□□□ □□□ □□□ □□□□ □□□□ □□□□□ □□□ □□□□ □□□□ □□□□□□□ - DXM □□□□ □□□□ □□ □□□□ □□□ □□ □□□ □□□□□ □□□□ □□□□□ □□□□ □□□ □□□□ □□□□□□□□
□□□□ 1-6	□□□□ NMDA □□□□□	□□□□□□ □□□□□ □□□□□	□□□□ □□ □□□□ □□□ □□□□□□□

	□□□□□ □□ □□□-1 □□□□□ □□□ □□ründ□□ □□□□ □□□□□ □□□□ □□ □□□□□□□□ HPPD □□□ □□□□□□ □□□ □□□□ □□□□□	□□□□ □□ □□□□□ □□□ □□□□□ □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□ □□ensive □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□ □□□□□□ □□□□□ □□□□ □□□□ (□□□ □□ □□□□□ □□□□ □□□□) □□□□ □□□	□□□□□ □ □□□□ □□□ (ADHD) □□□ □□□□□ □□□ □□□□□ □□□ DXM واقع□ □□□□ □□□□ □□□ - □□□ □□ □□ □□□ □□□ □□□ □□□□ □□□□ □□□□□

□□□ 4 - □□□□□□ □□□ □□□□

□□□□□ □□□□ □□□ □□□□□ □□□ □□ □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□ мат □□□□ (□□□□□ □□□□□□□□ □□□□), □□□□□ □□□□ (□□□□□□ □□□□□□□□ □□□□□ □□□ □□ □□□ □□□□□) □□ □□□□□□ □□□□□ □□□□ □□□ □□□□□ □□□□ (□□□ □□□□□ □□□ □□□□ □□□□□ □□□□ □□□ □□□□□). □□□□□ □□□ □□□□ □□□ □□□□□ □□ □□□□ □□□□ □□□

4.1 - □□□□□□ □□□□□□□

□□□□ □□□□	□□	□□□	DXM-□□□ □□□□□□□□
5-MTHF (L-□□□□□□)	□□□ 400-1000 □□□□ □□□□	□□ □□□ □□□□□	□□□□□ □□□□□ □□□□ □□□□□ - □□□ □□□□□□□□ (DXM) □□□□□□ □□□□□□□□ (SERT) □□ □□□□□□□□ □□□□ □□□□□□ □-MTHFR □□□□ □□□□ □□□□ □□□□ □□□□□□□ □□□□ □□□□□□□□□ □□□□ □□□□ 5-MTHF □□□□ □□ □□□□□ □□ □□□ □□□ □□ □□□ □□ □□□□□□ □□□□ □□□□ - □□□ □□□□□□ □□□□ □□ □□□□□□ □□ □□ □□□□ □□□□□□□□□ □□□□-1 □□ □□□□□ □□□□□□□□ (SERT) □□□□□□□ □□□□ □□□□□□
□□□□□□мін (□12)	1000–2000mcg □س□ □□□□ □□□□□	□□ □□□!	□□□□□ □12 □□□□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□ □□□□□□□ (DXM) □□□□□ □□□□□ □□□□ □□□ □□□□ □□ □□□□□□ □□□□ □□□□□ □□ □□□ □□□ □□□□ □□□□□ □□□□□□ □□□□□ □□□□□ □12 □□□□ □□□ □□□□□ □□□
P5P (□□□□ □□□□□ □ □□□□□)	25–50 □□□□	□□ □□□!	□□□□□□ □□□□ □□ □□ □□□□ □□□□□□ □□□ □□□□ □□□□□ (DXM □SERT □□ □□□□□□□ □□□□□) □□ □□□□ (NMDA □□□□) □□ □□□□ □□□□ □□□ □□ □□□□ P5P-□dependent □□□□□ □□□ □□□□□ □□□□□ □□□□□ □□□ □□ □□□□ □□□ □□□□ □□□ □□□□□□
□□□□□□ □□□□□□□□	400-600 □□ □□□ □□□ □□□□	□□ □□ □□□	□□□□□ NMDA □□□ □□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□□□□□ □□□□□ NMDA □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□ □□ □□□□□□ □□□□ □□□□□□□ □□□□□□□□□□□□ (DXM) □□□□ □□□ □□□□□□□□ □□□□ □□□□ □□□ □□□□□ □□□□ □□ □□□ □□□□□□ □□□□□

4.2 - □□□□□ □□□□□: □□□□□□□ (□□□□□□□□□) □□□□□ □□□□□□□ □□ □□□□□ □□□□ □□□□□ □□□□□

⚠ □□ □□□□ □□□□ □□□□□□□□□□□□□□□ (DXM) □□□□□ □□□□□ □□□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□□□□ (□□□□□□□□□) □□□□□ (□□□□ □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□)، □□ (NAC) □□□□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□□ □24-72 □□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□ □□□□ □□□□□□ □□□□□□

□□□□ □□□□ □□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□ (N-□□□□□□ □□□□□□)□ □□□□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□ □□بد □□□□ □□□□□ □□ □□□□□□□ □□ □□□□□□□□

- NAC 600–1200mg □□□□□ □□ □□□□□□□ □□□□□□□ □□□□□□□ (acetaminophen) □□□□□□ □□□□□ □□□□ □□□□ DXM □□□□ □□□□□ 24 □□□□□ □□□□ □□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□ IV NAC □□□□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□□□ □□□□ □□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□ □□□□□ □□□□
- □□□□□ □□□□ □□□□ □□□□□□□ □□□□□ (□□□□□ □□ □□□□ 4 □□□□ □□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□ □□□□) □□□□□□□ □□□□□ □□□□ (□□□□□□□□ □□) □□□□□ □□□□□ □□□□ □□□□□□□ IV (□□ □□□□) □□□□ □□□□□ □□□□□□ NAC□ □□ mouth (□□□□ □□□□) □□□□□□□ □□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□ □□ □□ □ □□□□□□□
- □□□□ □□□□□ □□□□□ (AST□ ALT□ □□□□□□): □□□□□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□□□□ □□□□□□
- □□□□□ □□□□□□ □□□□□ □□□□□□ □□□□: milk thistle (silymarin 200–400mg □□□□□), alpha-lipoic acid (300mg □□□□□), NAC (600mg □□ □□ □□□□) □□□□□ □□□□□□ (4–8 □□□□□□) □□□□□□□□□ □□□□□ □□□□ □□□□□□ □□□□□

4.3 - NMDA □□□□□ □□□□□ □□□□□□

□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□□□□□ (DXM) □□□□□□ □□□□□ □□□□□□

[□□□□ □□ □□□□□□□ □□□□□ □□□□ □□□□□□]

*   □□□□□□ □□□□□□□ □□ □□□□□ □□□□□□□□ □□□□ □□□□
*   □□□□□□□□□□□□□□ (DXM) □□□□□□ □□ □□□□□□□
*   □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□ □□□□□□□
*   □□□□□ □□□□□□□ □□ □□□□ □□□□□□□□
*   □□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□□□
*   □□□□□ □□□□□ (□□□□□ findahelpline.com)
*   □□□□□ □□□□□□ □□□□□□ □□□□ (□□□□□ Recovery Kernel, Naloxone, COMT, DRD2, MTHFR, Blueprint)

- NAC (□□ 600–1800 □□ □□□□ □□□□□ □□□□□□□□ □□□□ □□□□□ □□□□): □□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□ NMDA □□□□□□□ □□□□□□□ □□ □□□□□□□ □□□□□ □□□□□□ NAC-□□□□□□ □□□□□□-□□□□□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□
- □□□□□□□ □□□□□□ (□□ □□□□ □□□□ □□□□ □□ □□□□ 400-600 □□ □□□□ □□□□): □□□□□□ NMDA □□□□□□ □□□□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□□

- L-□□□□ (200–400 мг□ □□□□□ □□□□□): NMDA □□ جز□□ □□□□ □□□□□□ □□□□□ □□цин □□ □□□ NMDA □□□□□ □□ □□□□ □□□□□□□□ □□□□ □□□□□□ □□□□
- □□цин (3–5 □□□□ □□□): NMDA □-□□□□□ □□□ □□□□□ □□□ □□□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□ NMDA □□□□□□□ □□□□□□ □□□□ □□□□ □□□□ □□ □□□□ □□□ □□□□□ □□□□□
- □□□-3 □□تش□ (□□□ 2 □□□ □□): □□□□ □□□ □□□ □□□□ □□□□□□ □□□□ □□□□ □□ □□□□ □□□□□ □□□□ □□□□□□□ □□□□□□

4.4 - □□□□□ □□□ □□□□□

⚠ **5-HTP □ 3-5 □□□ □□□□□□ (DXM)** □□□□□ □□□ □□ □□□□ □□□□□ □□□ □□□ □□□□ □□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□ □□ □□□□ □□□□□ □□□□□ □□□ □□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□ □□□□ □□□ □□ □□□□□ □□□□ □□□□□□□

- 5-HTP (50–100mg□ □□□ - □□□□ □□□ □□□□ □□□ □□□): □□□□□ □□□ □□□□ □□□□□□□□□□□□ (DXM) □□□□□ (SERT) □□ □□□□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□□□□□ (SSRI), □□□□□□□□ (SNRI) □□□ □□□□□□ (MAOI) □□ □□□□ □□□□□□
- L-□□□□□□□ (500–1000□□□ □□□ □□□ □□□ □□□□ □□□□ □□): 5-HTP-□ □□□□□ □□□□ □□□□□ □□□□□□ □□□ □□□ □□□□□ □□ □□□ □□□□□□ □□□ □□□□ □□□□□ □□□□ □□ □□□□ □□□□□□□
- □□□□□ (4–8 □□□□ □□□□□□): □□□□□ □□□□ □□□□□□□ □□□□□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□ □□□ □□□ □□□ □□ □□ □□□□□□ □□□□□ □□□□□□ □□□□□
- EPA □□□□□ □□□-□ (□□□ □□□ 2-4): □□□□□ □□□□ □□□□□ □□ □□□□ □□□ □□□□□□

4.5 - □□□□□□ □□□□□□□ (DXM) □□□□□ □□□□ □□□□□□ □HPPD □□□ □□□□□□□

□□□□ □□□ □□□□ □□ □□□□□□□ (DXM) □□□□□ □□□□□ □□□□ □□ □□□□ □□□ □□□□ □□□ □□□□□□□□ (HPPD)-esque □□□ □□□□□ □□□ □□□□□□ □□□□□ □□□ □□□□□ □□ □□□□□□□□ □□ □□□□□ □ perceptual □□□□□□ □□□□ □□□ □□ □□□ □□□□□ □□□□□□ □□□□□□□□ □□□□□ □□□ □□□□□□ □□□□□□□ (DXM) □□□□□□□□ NMDA □□ □□□-1 □□□□□ □□□□□□ □□□ □□ □□□□□ □□□

- □□□□□□□□□□ (DXM) □□ □□□ □□□ □□□□□ □□□ NMDA □□ □□□-1 □□□□□ □□□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□ □□□□□□□□ □□□□□ □□□□ □□□□□□ □□ □□□ □□□ □□□
- □□□□ □□□: □□□□□□□ □□□□□□ □□ □□□□□ □□□□ □□□□ (HPPD) □□□□□ □□□ □□□□□ □□□□ □□□ □□□□□□□□□□□□ (DXM) □□ □□□□□□ □□□□ □□□□□ □□□ □□□□□□ □□□□□□ □□□□□ □□□
- □□ □□ □ □□□□□ □□□ 4-□□□□ □□□.□.□.□ □□□□□ □□□ □□□□□□ □□□ □□□□□□□□□□□ □□□□ □□□□ □□□□□□ □□□ □□□□ □□□□ (□□□□□ □□□-□□□□ Á□□□ □□□□□□ □□□□□ □□ □□تش□)□ □□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□□□□□ □□□□□□ □□□□□ (□□□ □□□□ □□□□□ □□□□□ □□□□)□

- [illegible] [illegible] [illegible]وقف [illegible] 4 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible] [illegible]) [illegible] [illegible] HPPD [illegible] [illegible] [illegible] [illegible]

4.6 - [illegible] [illegible] [illegible]

[illegible] - [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible] [illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] [illegible] "[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]" [illegible] [illegible] [illegible] [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

- [illegible] depressiveness [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] adolescent [illegible] [illegible] young adult [illegible] [illegible] [illegible] [illegible] [illegible] 5-MTHF [illegible] [illegible] (MTHFR-variant [illegible] depressiveness [illegible] [illegible] [illegible] [illegible]5 ـ-MTHF [illegible] [illegible] [illegible] SSRI [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]supplement [illegible] [illegible] depressiveness [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] SSRIs مناسب [illegible] [illegible] [illegible] DXM [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible]
- ADHD: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (stimulants) [illegible] [illegible] [illegible] [illegible] [illegible] (DXM) [illegible] [illegible] [illegible] (atomoxetine, guanfacine, viloxazine) [illegible]
- [illegible] [illegible] [illegible] disorder: [illegible] (DXM) [illegible]-1 [illegible] ([illegible] addictive), [illegible] [illegible] [illegible] (CBT)[illegible] [illegible] [illegible] (SSRI) [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible] [illegible] [illegible]) [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] (PTSD): [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] EMDR[illegible] CPT [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

4.7 - [illegible] [illegible]

- [illegible] [illegible] (400[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]): NMDA [illegible] [illegible] GABA [illegible]
- [illegible]цин (3-5 [illegible] [illegible] [illegible] 30 [illegible] [illegible]): [illegible] [illegible] [illegible] [illegible] [illegible] NMDA [illegible] [illegible]
- L-[illegible] (200[illegible] [illegible]): [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] (0.5-1 [illegible] [illegible]سل[illegible] [illegible] [illegible] [illegible]): [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- 5-HTP (50[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]): [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]/[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (4–8 Hz); [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

DXM-□□□□□ □□□□□□□ □□□□□ □□□□□□: □□□□□□ □□ □□□□□□ □□□□□□□ □□□□□□ - □□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□□

4.8 - □□□□□□ □□□□

□□□□□	□□□□ □-DXM □□□□□ □□□□□□ □□?	□□□□	□□□□□ □□□□□ * □□□ □□□□: **1-800-662-HELP (4357)** * □□ □□□□: **findahelpline.com** * □□□□□: **info@findahelpline.com** * □□□□□: **123 Main Street, Anytown, USA**
BPC-157	NMDA □□□□□□ □□□□□ □□□□□□□ □□□□□ □□ □□□□□□□ □□□□□ □□□□□ □□□□□-□□□□ □□□□□□ □□□□□□□□ □□□□□□ □□ □□□□ (□ □□□□□□□ □□□□□□□□□ □□□□□ □□□□)□	□□ 1 □□□□ - □□□□□	BPC-157 □□□□□□ □□□□□□ □□ □□□□□ □□□□□□□ □□□□□ □□□□ □□□□□□□□ □□□□□ □□□□ (NMDA, □□□□□□ □□ □□□□) □□□□□ □□ □□□□□□□ □□□□□□ □□□□□ □□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□□□ (acetaminophen) □□□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□ □□ □□ □□□□ □□□□
□□□□□	□□-□□□□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□ (□) □□□□□□□□ (DXM) □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ (□) □□□□□□□□□ □□□□□ □□□□ □□□□□□□□ NMDA □□□□□ □□□□ □□□□□□ □□□□□□ □□□□□□ □□□□ □□□□	□□□□□ 1-8 □□□□ □□□□□□□□□□	□□□□□□ □□□□□ □□□□□□ □□□□□□□□ (DXM) □□□□□□ □□□□□ "Sage COMT" □□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□-1 □□ □□□□□□□ (NMDA) □□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□ (Selank) □□□□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□ □□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□□ (intranasal) □□□□□ □□□□□□□□
Semax	BDNF □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□ (DXM) □NMDA □□ □□□□□□□□ □□□□□□ □□ □ADHD □□□□□□ □□□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□ □□□□□□ □□□□□ □□□□ BDNF □□□□□ □□□□ □□□□ □□□□□□□□	□□□□□ □□□□□ □□□□□	□□□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□□ □cloud□□ - □□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□□ □□□□ □□□□□□ - □□□□□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□ □□□□□□□ □□ □□□□□□ □□□□□ □□ □□□□□ □□□□□□ (ADHD) □□□□□□□□ □□□□□□ □□□□□ (Semax) □□□□ □□□□□□□ (BDNF) □□□□□□□□ □□□□ □□□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□□□ □□□□□

			□□□ □□□□□

□□□ 5 - □□□□□□□□□□□□ (DXM) □□□ - □□□□ □□ □□□□□□□.

□ □□□□□□□ - □□□□ □□□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□□

DXM □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□□□ □□□□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□□ □□ □□□□□ □□□□□□□ □□□□□انت □□□□ □□□□ □□□□ □□ □□□□□ □□□□□□□□□ DXM □□□□ □□□□□□ □□□□ □□□□ □□ 8 □□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□ □□□□ □□□□ □□□□ □□□□ 10 □□□□ □□□□ □□□□□ □□□□□□ □□□□

DXM □□□□□ □□□□□ □□□□□□□ □□□□□

□□□□	□□□□□□□ □□□□□	□□□□□□
□□□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□□□□□□ □□ □□ □□□□□ □□□□□□□ □□□□□ □□□□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□□□□	□□□□ □□□□□□□ □□ □□□□□□□□ □□ □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□ □□ □□ □□□□ □□□□□□□ □□□□□□ □□þun □□□□□□ □□□□□ □□□□□□-□□□□ □□□□ □□□□□□ □□□□□ □□□□□□	□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□ □□□□□□ □□□□ "cough & cold" □□□□ □□□□ □□□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□□ □□ □□□□□□□ □□□□□□ "10-minute rule": □□ □□□□□□ □□□□□□□ □□ □□□□□□ □□□□ 10 □□□□ □□□□□□
□□□□ depress □□□□□	□□□□□□□□□□□□□□□ (DXM) □□□□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□—□□□□□□ □□□□□□□□□ □□□□□□ □□□□□□ □□□□□□ NMDA □□□□□ □□ □□□□□□ □□□□□ □□□□□□□ □□□□— □□□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□	□□□□ depress □□□□□□□ □□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□ 5-MTHF□ □□□□□ □□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□ □□□□ depress □□□□ □□ □□□□□ □□□□ □□□□ □□ □□□□□□ □□□□□□ □□□□□ □□□□ depress □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□□□□ □□□□□□ □□ □□□□□ □□□□□□□
□□□□□□□ □□□□ - □□□□ □□ □□ □□□□□ □□ □□□□ □□□□□ □□□□□□□ □□□□□□	DXM □ □□□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□ □□ □□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□ □□□□□ □□□□ brain□ DXM □ □□□□□□ □□□□ □□□□□□□□ □□□□□□□ □□□□□□ □□ □□□□□□□ □□□□□□ □□□□□ □□□□□ (boredom) □□ □□□□□□ (loneliness) □□□□□ DXM □ □□□□□□□ □□□□□□□ □□□□□	□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□ 05□ □□□□□□□□□□□□□□ (DXM) □□□□□ □□□□□□□□ □□□□□ DXM □ □□□□□ □□□□□□□ □□ □□□□ □□ □□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□□ □□ □□□□□ □□□□ (ADHD) □□□□□□□—□□□□□ □□ □□□□ □□□□□□□□□□□□□ □□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□—□□□□□□□ □□□□□□ □□□□□ □□□□
□□□□□ □□□□□ - □□□□□□ □□□□□□ □□□□□□	DXM-□ □□□□□□□ □□□□-1 □□□□□□ □□ □□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□ □□□□□□ □□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□□	4-7-8 □□□□□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□□ (□□□□□□□ □□□□□ □□□□□□□ - □□ □□□□ □□□□□□□ □□□□

	[illegible] DXM-[illegible]	[illegible]). [illegible]
[illegible] / [illegible]	DXM [illegible]-[illegible] - [illegible] - [illegible]	[illegible] 05 [illegible] DXM [illegible]

[illegible] (DXM) [illegible] - 5 [illegible] ([illegible] 10 [illegible])

1. [illegible] "10 [illegible]" [illegible]- [illegible] 10 [illegible]
2. 4-7-8 [illegible]
3. NAC [illegible] ([illegible]) [illegible] NMDA [illegible] (glutamate) [illegible] craving-[illegible] craving [illegible]
4. [illegible]? [illegible]? [illegible]? [illegible]? [illegible]? ADHD? [illegible]
5. [illegible]
6. [illegible] (OTC) [illegible]—[illegible]—[illegible] secretive [illegible]
7. [illegible]- [illegible] meditasyon[illegible]

□□□ 6 - □□□□□□ □□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□□□□ (DXM) □□□□□ □□□□□□ □□□□□

□□□□□□□ - □□□□□□ □□□□ □-28 □□□□□□□ □□ □□□□ - □□□□□ □□□□ □□□□ □□□□

DXM □□□□□ □□□□□ □□ □□□□□ □□□□ □□□□□ □□□ □□ □□□□□ □□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□

- □□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□стествен □□□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□ (meditation) □□□□□□□ □□□ □□□□ (DMN) □□□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□ (NSDR)/□□ □□□□□□ □□ลม□□ □□ □□□□ □□□□ □□□□ □□□ □□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□
- □□□□□□□□ □□□□ □□□□□ □□□ □□□ MDMA □□□□□ □□□□□ □□□□□□ □□ - □□□□□ □□□ □□ □□□□□□ □□□□□□□ □□ □□□□□ □□ □□□□□ □□□□□□ □□□□ □□□ □□□□□□□ □□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□□□□□□
- □□□□□□□□ □□□ □□□□□ □□□□□ □□□□□□□□ □□□□□□□ □□□□ □□□ □□□□—□□□□□ □□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□□structured □□□ □□□□□
- ADHD □□□□ □□□□□□: ADHD □□□□ - □ stimulating □□□□ □□□□□□□ □□□□□ □□□ □□□□□□ □□structured □□□□□ □□□□□ "compendium" □□□ □□□□ □□□□□ □□□□□□□□ □□□□□ □□ □□□ □□□□ □□□□□ □□□□□□□ □□□□□ □□□□: □□□□ □ martial arts □□□□□□ □□□□□ □□□□□ □□□ □□ □□□ □□□ □□□□□ □□ □□ □□□ □□□□.

□□□□□ □□□□ □□□□□

DXM □□□□□□ □□□□ □□□□□- * □□ □□ □□□□□ □□□□□□ * □□□□□□□□□ □□□□□ □□□□□□□ * □□□ □□□□□ □□□ □□□□□ □□□ □□□ □□ □□□ □□ □□□ □□□□□	□□□□□ □□□□□	□□□□ □□□□□ □□□□ □□□□?	□□□ □□□□□□□□□□□□□ **(DXM)** □□□□ □□□□□□□ □□□□
□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□	□□□□ (□□□□ □□□□□); NSDR; □□□□□□ □□□□□□□	□□ □□□ □□□ - □□□□ □20 □□□ □□□□□ □□□ □□□□ (□□□□□ 04). □□□□□□□□: □□□□ 20-30 □□□□ motionless □□□ □□□□ □□□ □□□□ □□□□□ □□□□□□□□ □□□□□□ □□ □□□□□ □□□	DXM-□□□ □□□□□□ NMDA □□□□□□□□□□ □□□□□□□□ □□ □□□□ (meditation) □□□ □□□□ □□□□□□ □□□ □□□□□ □□□ DXM □□□□□ □□ □□□□ □□□ □□□ □□□□□ □□□ □□ □□□□□□□□□ □□□ □□□ □□ □□□□□ □□ □□□□ □□□ □□□□□ □□□□ □□ □□□□ □□□□□
□□□□ □□□ □□□□ □□ □□□ □Відчуття	□□□□ □□□ □□□□□□□ □□□□□	□□ □□□ □□□□ □□□ □□□□ □□□□□□ □□□□□ □□□ □□	□igma-1 □□ □□□□□ □□□□□□□ □□□□□□ (DXM) □□□□□ □□ □□□ □□□□ □□ □□□□ □□□□□□ □□□ □□□□□ □□□□

тепла (□□□-1 + SERT).	□□□□□□□ □□□□□□□ □□□□ □□□□□	□□□□□□ □□ □□□□□□□ □□□□□ □□□□□□ □□divertissement (divertissement). □□□□□ □□□□ □□□□ □□□□ □□□□□□	□□□□□□ □□ □□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□ (DXM) □□□□□□□□□ □□□□□ □□□□ □□□□□ □□□□ □□ □□□□□□ □□□□□□□ □□□□□ □□□□□□ □□ □□□□□□ □□□□□□
□□□□□□ □□□□□ □□□□□	□□□□□□□ □□□□□ □□□□□□ □□□□□ buspirone □□□□□□□ □□□□□□ □□□□□□ □□□□□ □□ □□□□ □□□□□□□ □□□□ □□□□□□	□□□□□□ □□□□□ □□□□□ □□□□□□ (MBSR□ □□□□□□□ □□□□□□□□ θεραπεία □□□□□□ □□□□ θεραπεία). □□ □□□□ □□□□□ - □□□□□□□ □ □□ □□ □□□□□□□ □□□□□ □□□□□□ Buspirone (□□□□□ □□□□□ □ addictive □□□□□ □□□□□□).	□□□□□□□□ (DXM) □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□-1 □□ □□□□□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□□□□ □□□□ □□ □□□□ □□□□□□ □□□□□□ □□□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□□ □□□□ □□□□□□
□□□□□□ □□□□ □□□□□	□□□□□□□ □□□□□□ □□□□ □□□□□□ □□□□ breathing □□□□□□ □□□□□□ □□□□□□	□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□ □□ □□ □□□□□ □□□□□□□□ □□□□□	DXM □□□□ □□□□□□ □□ □□□□□ □□□□□□□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□ □□□□□□□□□ □□ □□□□□□□□ □□□□□□□ □□□□ □□□□□□□□ □□□□□ □радиції □□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□□□□□ DXM □□□□□□□ □□ □□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□ □□□□ □□ NMDA □□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□
□□□□□□□ □□□□□□ □□□□□□ - □□□□□ □□ □□□□ □□□□□□	□□□□□□□ □□□□□ (□□□□□□□□ + □□□□□□ □□□□□); □□□□□; □□□□□□□□ □□□□□; □□□□□ □□□□ □□□□□□□□	□□□□□□□ □□□□□ □□ □□□□ □□□□□ □ stimulating □□□□ non-stimulating □□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□□□ (30–45 □□□)□ □□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□ □□□□ □□□□□□□□□□□ □□□□□ □□□□ □□□□ □□□□□□□□ □□□□ □□□□ □□□□ □□ □□□□□□	□□□□□ □□□□□ □□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□ * DXM □□□□□□ □□□□□□□□□□□□□ (ADHD) □□□□□□□ □□□□□□□□ □□□□ □□ □□□□□ □□□□□□□□□□□□ □□□□□□ DXM □ □□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□ □□□□□ □□ □□ □□ □□ □□□□ □□□□□□ □□□□□ □□ □□□□ * □□□□□□□□□□□□□ □□□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□ □□□□□□ DXM □□□□□ □□□□□ □□□□□□ □□□□□□□ healthy □□□□ □□□□□ □□□□

□□ adolescent-specific □□□□□ □□□□□□□□□

□□□□ - □□□□□□□ □□□□ □□ □□□□□ □□ □□□□ □□□□□□□ □□ □□□□□□

DXM □□□□□□□ □□□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□□□□□ □□ adults □□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□ □□□□□□□ □□□□□ □□□□□

- □□□□□ □□□□□□ □□□□□□□□ □□□□□ □□□□ □□ □□□□□□ □□□□ □□ □□□□□□ □□□□□ □□□□ □□ □□□□□□□ □□□□□ □□□□□□□□ □□□□□□□ □□□□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□ □□ □□ □□□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□□

- [illegible] [illegible] [illegible] [illegible] [illegible]ULTS[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (DXM) [illegible] [illegible] [illegible]—[illegible] [illegible] "[illegible] [illegible] [illegible]" [illegible] [illegible]—[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] θεραπεία [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (ADHD) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□ 7 - "□□□□ □□□□□"□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□

□□□	□□□□□□□	□□ □□□□□	□□□□□□□□□□□□ (DXM) □□□□□□ □□□□□□□□
□□□□□ □□ □□□□□□ □□□□ (□□□ 0-7)	□□□□ □□□□□ □□□□ □□□□□ □□□ □□□□ □□□ 0□	□□□□□□□ □□□□□□ □□□□□ □□□ (NAC) □□□□ □□□ □□□□□□□ □□□□ □□□□ □□□□ □□□ □□□□□	□□□□□□□□□ □□□□□□□ □□□ □□□ □□□□□ NAC □□□□ □□ □□□□□□ □□□□ □□□ □□□□ □□□ □□□□ □□□□ □□□□□□ □□□ □□□□ □□□□□□ □□□ □□□ □□□□□ □□ □□□□□ □□□ □□□□ □□□ □□□□□□□□ □□□□ DXM □□□□ □□□ □□□ □□□□ □□ □□□ □□□□ □□□□□ □□□□ □□□ □□□□ □□ □□□□□ □□□□ □□□□□□□
□□□□□ □□□ □□□□ (□□□ 1-14)	□□□□□ 07□ □□□□□ 09□ □□□□□ 17□	NAC (NMDA □□ □□□), □□□□□□□ 5-MTHF□ □□□□□ □□□□□ □□□□ □□□ □□□□ L-□□□□□ □□□□□□	NAC □□□□□□□ □□ - □□ □□□□□ □□□ □□□ □□□□□□□ □□□□□ (NMDA □□□□ □ □□□□□□ □□ □□□□□ □□□). □□□□□□ □□□□□□□ □□□ 5-MTHF □□□□□□□ □□□ 5-HTP: □□□ □□ □□□□□□ □□□□□□□ □□□□□□□ DXM □□□□□ □3-5 □□□ □□□ □□ □□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□
□□□□ □□□ (□□□□□ 1-4)	CYP2D6 □□□□□ SLC6A4□ COMT□ MTHFR□ DRD4/DAT1.	CYP2D6 □□□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□	CYP2D6 □□□□□□□□□ □□□□ □□□ □□□ □□□□ □□□□ □□□□□ □□□□ □□□□ □□□ □□ □□□□ □□□ □□□□□□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□ ADHD □□□□ □□□□□ (DRD4, DAT1) ADHD □□□□ □□□□□ □□□□ □□□□□□
□□□□ □□□□□ □□□□ (□□□□ 2-12)	□□□□ □□□□ □□□□ □□□□□□□ ADHD □□□□□ □□□□ □□□□□□ θεραπεία (CBT)□ □□□ 4.6□	□□□ depress □□□□□□ □□□□□□ (ADHD) □□□□ □□ □□□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□ □□□□ □□□ □□□□□	□□ □□□ □□□□□ □□□□ □□□ □□□□ □□□ □□□□□□□□□□□□ (DXM) □□□□ □□□□ □□□ □□ □□□ □□□ □□□□□ □□□□ □□□ □□□□□□□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□ □□□ □□□□ □□□□□
HPPD □□□□□□□ (□□□□ □□□□□ 1-8).	□□□ 4.5 □□□ □□□□ □□□□ □□□ □□□ □□□□ □□□ □□□□□□□	□□□□ □□□ □□□□ □□□□□□□□□ □□□□□ □□□□□□ □□□□ □□□□□	DXM □□□□□□ HPPD □□□ □□□□□□□ □□□□□□□□ □□□□□□ HPPD □□□ □□□□ □□□ □□□ □□□ □□□ □□□□□ □□□□□ □□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□ □□□ □□□□□ □□□ □□□□ □□□ □□□□□□ □□□□ □□□□□ □□□ □□□ □□□□□ □□□□ □□□□□□ □□□□ □□□
□□□□□□ □□□□ □□□□□□□ (□□□ 1-6)	□□□□□ 04 (□□□□□), □□□□□ 03 (□□□□ □□□ □□□□□□), □□□	□□□□ □□□□/□□□□□ □□□□; □□□□ □□□□ □□□ □□□□□□; □□□□□□; □□□ □□□ □□□□□□ □□□□□ □□□□□ □□□□□	□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□□□ * □□□□ □□□ □□□: □EDY□ція + □□ relaxing (NSDR). * □□□□ □□□□ □□□□: □□□□ □□□ □□□□□□

	□□□□ □□□ 6□		+ □□□□□. * □□□□ □□□□ □□□□□□□ □□□□: □□□□□ □□□□ (CBT) + □□□□□ □□□ □□□□□ * ADHD □□ □□□□ □□□□ □□□□: ADHD □□□□ + □□□□ □□□ □□□□□□. □□□□□□□□□ □□□□□□ □□□□□ □□□□□ □□□□ □□ □□□□□□ □□□
□□□□□ □□□□ □□ □□□□ □□ □□□ (□ □□ □□ □□□ □□□)	□□□□□ 20□ □□□□□ 21□ □-28□ □□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□	□□ □□ □□□□□□□ (DXM) □□□□□ □□□□ □□□ □□□□? □□□ □□□□□ □□□□ □□□□ □□□ □□□□ □□□□ □□ □□□□ □□?	□□□□□ □□ □□□□□ □□□□□□ □□□□□□□ □□ □□□□ □□□□□□ □□□ □□□□ □□□□ □□□ □□□□□□ □□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□□ - □□□□ □□□□□□□ □□□□□ □□□□□□ □□□□ □□□ □□□□□□ □□□□□□ □□□□□ □□□□□ □□□□

□□□ 8 - □□□□□□ □□□□□□□□ □□□□□ □□□□□

DXM □□□□□ □□□□□ □□□□□□□ □□□ □□□□ □□□□□□ □□□□□ □□ □□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

□□ □□□□□ □□□□□ □□□ □□ □□□ □□□ □□□□□□ □□□ □□□ □□□□□ □□□□□ □□□□□□□□ □□□□□ □□ □□□ □□□□□ □□□□□ "□□□□□ 13" (□□□□ □□□□□) □□□□ □□□□□□□

8.1 - □□□□□□□□□□□□ (DXM) □□□□ □□□ □□□ □□ □□□□□ □□□□□□□

- □□□□□ □□□□□ AST□ ALT□ □□□□□ □□ GGT - □ □□□□□ □□□□□□ □□□□ □□□ □□□□□□□ □Patients□ □□□□□ □□ □□ □□□□ □□□ □□□ □□□□□□ □□□□□ □□□□□ □□□□□ □□□ □□□□ □□□□ □□ □□ □□ □□□□□ □□□□ □□□□ □□□□□□□
- CYP2D6 □□□□□ □□□□□□□□□□□□ (DXM) □□□ □□□□□ □□□ □□□ □□□ □□□□ □□□□□□□□□ □□□□ □□□ □□□□□ □□□□ CYP2D6 □□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□
- □□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□□ □□ □□□□□ □□□□ □□□ □□ □□Patient □□□□□ □□□□ □□□ □□□□□□□□ □□□□□ □□ □□□□ □□□ □□□□ □□ □□□ □□□□□ □□□□ □□□□□□ □□□□□
- □□□ depress □□ □□□□: PHQ-9 □□ GAD-7 □□□□ □□□□□□ □□□□□□□ □□□ □□□ □□□□□ □□□□□□□ □□□ □□□□□ □□□□ □□ □□□□□ □□□ □□□□□ □□ □□□□□□□ □□□ □□□ □□□ □□□□ □□□□ □□□□ □□□□□□□
- □□□□□□□□ □□□□□ □□□ □□□ □□□□ □□□ □□□ □□□□□ □□□ □□□ □□□ □□□□ □□□□ □□□□ □□□ □□□□□ □□□□ □□□□ □□□□ □□□ □□□-□□□□ □□□□ □□□□□ □□□□□□□ □□□□□□ □□□□ □□□□ □□□□□ □□□-□□□ □□□□ □□□ □□□□□ □□□□ □□□□□□□ □□□□ □□ □□□□ □□□ □□□□□

- □□□ □□□□□ □□□□ □□□□□□□□□ □□□ □□□□□ □□□□ □□□ □□□□□ □□□□□□ □□□□□□□□□□□□□□ □□□ □□□ □□□□ □□□□ □□□□□□

8.2 - □□□□ □□ □□□□□□

□□□□ □□□□□ □□□□□ □□□□ □□□□□□□□ □□□ □□□ "□□cough syrup □□□□□ □□□" □□□□ □□□□□ □□□□ □□ □□□ □□□ □□□□□ □□□ □□□ □□□□□□ □ clinica□ □□□□□ □□□□ □□□ □□□ □□□□□□□ □□□□ □□□□□

"□□□□□□□□□□□□□ (DXM) □□□□ □□□ □□□□□ □□□□□ □□□□□ □□ □□□□ □□□□□ □□□ □□□□□□ □□□ □□□ [X] □□ □□□ □□ □□□□ □□ [□□□□□□ □□] □□□ □□ □□□ [□□□□□□ NMDA □□ □□□□□ □□□□□ □□□□ / □□□□□ □□□□ □□□□□ / □□□□ □□□ / □□□□ □□□□□□] □□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□ □□□□ □□□□ □□□□ worry □□ □□ □□□□ □□□□ □□□□ □□□□□□□ □□□□□ CYP2D6 □□□□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□ □□□□ □□□□□□ ADHD/□□□ depress/□□□□ □□□ □□□□ □□ □□□□□□ □□ □□□ □□□ □□□□ □□□□ □□□□ □□□□□□□□"

□□□ □□□□□□ □□□ □□□□□ □□□□□ □□ □□□□ □□□ □□□□ □□□□ □□□

8.3 - [illegible]

- DXM [illegible]: [illegible] DXM [illegible] (18+) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] CVS Pharmacy DXM [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- DXM [illegible] [illegible] [illegible] Maßnahmen- Erowid [illegible] [illegible] DXM [illegible] (erowid.org/chemicals/dxm) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] DXM [illegible] [illegible] [illegible] [illegible] [illegible] (FAQ) [illegible] [illegible] [illegible]
- SAMHSA's Treatment Locator (findtreatment.gov): while DXM is rarely listed as a primary substance, substance use disorder treatment for comorbid depression, ADHD, and anxiety is appropriately addressed through the standard treatment locator.
- [illegible] [illegible] [illegible] 1-800-852-8336 ([illegible] [illegible]) - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] "HOME" [illegible] [illegible] 741741 [illegible]

[illegible]

[illegible] - [illegible]

DXM [illegible] Adolescent[illegible] - [illegible] ADHD [illegible] تب [illegible]

[illegible] (C-37) [illegible] (DXM) [illegible] (NMDA) [illegible]-1 (sigma-1) [illegible] (serotonergic) [illegible] - [illegible] випадкові [illegible] вро[illegible]

[illegible]OTC ([illegible]) [illegible] (DXM) [illegible] coughing [illegible] Robitussin [illegible] "[illegible]?" [illegible]crete [illegible]

[illegible] MTHFR-variant [illegible] 5-MTHF [illegible] SSRIs [illegible]ADHD [illegible] DXM [illegible]-[illegible] CBT [illegible] sigma-1 [illegible]-[illegible] contemplative [illegible] DXM [illegible] NMDA [illegible]

[illegible] "[illegible]" [illegible]

[illegible] (DXM) [illegible]

— — —

DXM [illegible] erowid.org/chemicals/dxm | [illegible]: 1-800-852-8336 |
[illegible] "HOME" [illegible] 741741 [illegible]

[illegible] (Recovery Kernel) [illegible]

Crisis: call or text 988 | Emergency: 911 | SAMHSA: 1-800-662-4357

⚠ [illegible] - [illegible]

DXM [illegible] "[illegible]" [illegible] | [illegible].